Search results
Novartis' (NVS) Shareholders Approve Sandoz Separation
Zacks via Yahoo Finance· 8 months agoNovartis AG NVS announced that its shareholders agreed to the proposed 100% spin-off of its generic...
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
Zacks via Yahoo Finance· 10 months agoSwiss pharma giant Novartis AG NVS reported strong second-quarter 2023 results and shares are...
Novartis (NVS) Plans to Spin Off Generics Business Sandoz
Zacks via Yahoo Finance· 2 years agoNovartis NVS has announced plans to spin off Sandoz, its generics and biosimilars division, into a...
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
Zacks via Yahoo Finance· 2 years agoNovartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight...
Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK
Zacks via Yahoo Finance· 4 months agoThe fourth-quarter 2023 reporting cycle of the Medical sector is about to pick up pace this week....
Novartis Shares Rise After Full-Year Guidance Confirmed
Investing.com via Yahoo Finance· 2 years agoBy Scott Kanowsky Investing.com -- U.S.-listed shares in Novartis AG ADR (NYSE:NVS) climbed on Tuesday after the Swiss drugmaker confirmed its group guidance for 2022 core operating income to ...
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
Zacks via Yahoo Finance· 1 year agoBayer AG BAYRY released first-quarter 2023 core earnings of 79 cents per American Depositary Receipt...
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoIncyte Corporation INCY is scheduled to release its second-quarter 2022 results on Aug 2, before the...
Weekly Upgrades and Downgrades
InvestorPlace via Yahoo Finance· 2 years agoDuring these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking...
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
Zacks via Yahoo Finance· 2 years agoSanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung...